Kura Oncology plans Phase 1a platform study pairing darlifarnib with daraxonrasib in KRAS-mutant pancreatic cancer

Kura Oncology

Kura Oncology

KURA

0.00
  • Kura Oncology outlined a development strategy for darlifarnib as a combination backbone in KRAS-mutant cancers, citing early clinical activity.
  • Preliminary Phase 1a results were presented at the 2026 ASCO meeting, showing tumor responses across pancreatic, lung, and colorectal cancers.
  • The readout suggested improved outcomes versus historical KRAS inhibitor use, supporting broader combination development beyond KRAS G12C.
  • A new platform study is planned to test darlifarnib with multiple targeted therapies, with successful arms intended to move into registrational studies.
  • The first planned platform combination, darlifarnib with daraxonrasib in second-line or later KRAS-mutant pancreatic cancer, is expected to enter Phase 1a in early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030653PRIMZONEFULLFEED9731046) on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.